Geneva-based Alys Pharmaceuticals secures $100million in funding from Medicxi. Co-founded by Medicxi and a number of internationally renowned dermatologists and scientists, including John Harris (UMass Chan Medical School).
Eric Deutsch (Gustave Roussy), Craig Mello (UMass Chan Medical School), Brian Kim (Icahn School of Medicine at Mount Sinai), Lars French (LMU, Munich), and Mark Prausnitz (Georgia Institute of Technology) are the Nobel laureates.
Read also – AZ-based Vensure Employer Solutions Acquired MarathonHR
Co-founder and COO Thibaud Portal, who was previously Global Head of Prescription Medicines at Galderma, is in charge. Alys develops its pipeline of 14 active programs, targeting various dermatological indications such as vitiligo, psoriasis, mastocytosis, and atopic dermatitis. It does this by combining the platforms and assets of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences, and Vimela Therapeutics.
Alys expects its platforms—which address autoimmune disorders, uncommon dermatoses, inflammatory illnesses, and dermatological supportive care for cancer patients—to continue growing organically in the pipeline.
Read also – PA-based Formlogic Secures $20Million in Funding
The company plans to provide seven to ten clinical Proof-of-Concept (POC) readouts in the next three years, with the possibility of at least one program moving forward to registrational studies.
In order to achieve this, Alys collaborates with organizations including the Swiss Federal Laboratories for Materials Science & Technology (Empa), Institut Gustave Roussy, UMass Chan Medical School, Icahn School of Medicine at Mount Sinai, Georgia Institute of Technology, and others.
Read also – CA-based Encore Consumer Capital Secures Encore Consumer Capital Fund IV at $258M
About Alys Pharmaceuticals
Alys Pharmaceuticals, a global leader in immuno-dermatology innovation, was created in February 2024 by world-renowned dermatologists and scientists, including Medixci. Alys, which was formed by combining six asset-focused Medixci companies, has a strong pipeline of cutting-edge platforms and initiatives that address various dermatological indications.
Read also – NC-based Volta Insite Secures $7Million in Seed Funding
